News Three more biotechs price their Nasdaq IPOs AgomAb, SpyGlass, and Veradermics have all set the terms for their IPOs this week, looking to raise somewhere between around $150m and $200m.
News Eikon prices its IPO, seeking to raise $318m Roger Perlmutter's new cancer biotech Eikon has priced its IPO, looking to raise up to $318m and achieve a $900m-plus valuation.
News UK biotech sees "strong finish" to 2025 financing 2025 was a challenging year for the UK biotech sector, but it ended the year with signs of "renewed confidence," says the BIA industry body.
News Corxel's raises $287m for obesity drug, and other financings Our latest biofinancing round-up sees big rounds for Corxel and Caldera, with Mendra, Think Bio, Exciva, Cytotheryx, and Infinitopes also raising cash
News AgomAb and SpyGlass push the IPO button Glimmers of a renewal of biotech IPO activity in 2026 have continued with the news that AgomAb and SpyGlass Pharma are sizing up investor interest.
News Perlmutter's Eikon follows the IPO trail Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.